Because thats, in essence, exactly what Novalere has done.. Once Fluticare is approved Novalere and Innovus effectively merge companies and Novalere becomes a 49% stakeholder in Innovus. Novelere themselves did not have the experience and know how to take this product to OTC so they did exactly what they should have and made a deal with a company/mgmt with experience so both could benefit from the synergies to come.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.